Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Investor Presentation (October 2023)
22 slides from Cantargia Ab's investor presentation, October 2023
Slide 1: Targeting IL1RAP to address unmet needs in severe cancer and autoimmune diseases
Targeting IL1RAP to address unmet needs in severe cancer and autoimmune diseases Corporate Presentation Oct 2023 NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and
Slide 3: Cantargia – Investment highlights
Cantargia – Investment highlights NOVEL IL1RAP ANTIBODIES, POTENTIAL TO TREAT CANCER & INFLAMMATORY DISEASE • IL1RAP elevated in most solid and liquid tumors • IL1RAP signalling drives several autoimmune and inflammatory diseases NADUNOLIMAB: CLEAR ACTIVITY SIGNALS IN CANCER THERAPY WITH UPCOMING CA
Slide 4: Current pipeline
Current pipeline Project Disease Type of Discovery Preclinical Clinical Clinical Clinical ' treatment — phase phase phase | phase Il phase III PDAC 1st line Gemcitabine/nab-paclitaxel Nadunolimab TNBC 49/2" line Carboplatin/gemcitabine or sa non-squamous NSCLC 154/26 line Platinum doublets Spent -_—
Slide 5: Nadunolimab (CAN04) Clinical Results
CONFIDENTIAL NADUNOLIMAB (CAN04) CLINICAL RESULTS
Slide 6: New strategy to treat cancer supported by clinical results
New strategy to treat cancer supported by clinical results PROMISING DATA IN PANCREATIC CANCER → Stronger efficacy than expected from chemotherapy alone (survival 13.2 mo vs <10 mo in historical controls) → Patients with higher IL1RAP level benefit more Nadunolimab Durable response Primary Chemo- Sh
Slide 7: PDAC – Staging and treatment
PDAC – Staging and treatment Expected number of cases US 2023: 64,000 Stage I - local: 3,200 Stage II - regional LN; 3,200 Stage IV - Stage III - metastatic: locally adv: 32,000 25,600 Stage I Stage II Stage III Stage IV RESECTABLE OR BORDERLINE RESECTABLE DISEASE LOCALLY ADVANCED OR METASTATIC DISE
Slide 8: PDAC – Positive interim data in 1st line patients
PDAC – Positive interim data in 1st line patients Best responses according to iRECIST OS and iPFS for mITT patients Nadunolimab combination 50% Best change in tumor size with Gem/Abraxane in 1st line PDAC (n=73): 0% → 33% response rate with long PFS and OS -50% → Additional 5 (7%) patients had on-tr
Slide 9: PDAC – Strong efficacy in patients with high tumor IL1RAP level
PDAC – Strong efficacy in patients with high tumor IL1RAP level IL1RAP High IL1RAP Low 50% Best change in tumor size iCPD 0% iUPD iSD iPR -50% -100% Efficacy analysis for IL1RAP High (n=29) vs IL1RAP Low (n=20) PDAC patients: → Significantly prolonged survival in ILRAP High vs IL1RAP Low patients (1
Slide 10: PDAC Monotherapy - strongest treatment effect in patients with high IL1RAP
PDAC Monotherapy - strongest treatment effect in patients with high IL1RAP OS iPFS Monotherapy efficacy analysis for IL1RAP High (n=5) vs IL1RAP Low (n=12) PDAC patients: → Significantly prolonged iPFS in ILRAP High vs IL1RAP Low patients (3.6 vs 1.6 mo; p=0.0073) → Trend for survival advantage in H
Slide 11: PDAC – IL1RAP linked to poor prognosis
PDAC – IL1RAP linked to poor prognosis IL1RAP in PDAC → IL1RAP levels increase with tumor stage and KRAS mutations → IL1RAP on both tumor cells, cancer associated fibroblasts and macrophages in tumor microenvironment → High IL1RAP correlates with lower efficacy after first line gem/abraxane CLEAR LI
Slide 12: PDAC – Upcoming phase IIb study design
PDAC – Upcoming phase IIb study design Analysis Groups All Nadunolimab 80 mg + G/nabP Treatment groups Randomized N = 150-200 Nadunolimab 200 mg + G/nabP 1:1:1 G/nabP High Low IL1RAP IL1RAP PHASE IIB TRIAL TO VALIDATE STRONG SIGNAL OF ACTIVITY IN IL1RAP HIGH PATIENTS 12
Slide 13: NSCLC – Long-term benefit with strong signal in non-squamous subtype
NSCLC – Long-term benefit with strong signal in non- squamous subtype Non- Treatment course for each individual patient All Historical Non-squamous squamous, (n=30) data1,2 (n=16) CR1 historical data3 Median OS 13.7 mo 10.3 mo 15.9 mo 11.3 mo CR2 Median PFS 7.0 mo 5.1 mo 7.3 mo 4.9 mo OS ORR 5
Slide 14: TNBC – Promising early safety and efficacy
TNBC – Promising early safety and efficacy Best responses according to RECIST Nadunolimab combination with Gem/Carbo in 100 % 1st/2nd line metastatic TNBC: Best change in tumor size 15 patients enrolled in the dose-escalation phase 50 % PD → Acceptable safety profile (G-CSF given prophylactically to
Slide 15: CAN10 – Opportunity in Autoimmune/Inflammatory Disease
CAN10 – OPPORTUNITY IN AUTOIMMUNE/INFLAMMATORY DISEASE
Slide 16: CAN10: Indications and preclinical development
CAN10: Indications and preclinical development → Inflammation of the myocardium that can lead to → Chronic, autoimmune connective tissue disorder fibrosis and loss of contractile function characterized by inflammation and fibrosis of the skin and internal organs → Can be both autoimmune and viral →
Slide 17: Systemic sclerosis: mCAN10 inhibits bleomycin-induced skin fibrosis
Systemic sclerosis: mCAN10 inhibits bleomycin-induced skin fibrosis Bleomycin (BLM) model mCAN10 10 mg/kg twice W BLM 2.5 mg/kg (daily s.c.) Nintedanib 50 mg/kg QD C57BL/6 Established fibrosis Termination n=10 per group Week 3 Week 6 No BLM (6 wks) Baseline BLM (3 wks) Dermal thickness Myofibroblast
Slide 18: Viral myocarditis: mCAN10 reduces disease severity
Viral myocarditis: mCAN10 reduces disease severity CVB3 myocarditis experimental design CVB3 Echocardiography → mCAN10 reduced disease severity, based on histological scoring of heart sections, and Balb/c ♂ 10 d.p.i. preserved heart function 10 weeks old Peak of inflammation 4 *** → mCAN10 also redu
Slide 19: CAN10 – Project status
CAN10 – Project status Status → CAN10 safe in GLP tox study → Strong results in preclinical models of several diseases including lead indications myocarditis and systemic sclerosis → Phase I ongoing, early planning of patient studies (phase IIa) Clinical phase I study – First data set during 2024 →
Slide 20: Milestones & Investment Highlights
MILESTONES & INVESTMENT HIGHLIGHTS
Slide 21: Solid financial position with strong shareholder support
Solid financial position with strong shareholder support → Cash and cash equivalents SEK 287 M at end of Q2 2023 Current owners (Jun 30, 2023) 4th AP fund 8.8% → Runway until mid/end-2024 1st AP fund 6.3% → Market cap appr 0.8 BSEK, Oct 6, 2023 Alecta 6.0% Six Sis AG 5.0% Avanza Pension 4.9% Swedban
Slide 22: Upcoming milestones
Upcoming milestones Nadunolimab Additional PDAC NSCLC TNBC CAN10 milestones • New translational • Efficacy/biomarker • Randomized Phase II • Phase I recruitment • New clinical data data Q3 2023 data from CANFOUR (TRIFOUR) – interim and treatment presented from 2023 and 2024 futility analysis in Q4 o